AUTHOR=Hsieh Meng-Che , Rau Kun-Ming , Lin Shung-Eing , Liu Kuang-Wen , Chiu Chong-Chi , Chen Chih-I , Song Ling-Chiao , Chen Hsin-Pao 

TITLE=An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.867546

DOI=10.3389/fonc.2022.867546

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>There are no randomized control trials comparing the efficacy of trifluridine/tipiracil and regorafenib in patients with metastatic colorectal cancer (mCRC). Herein, we conducted an observational study to compare the oncologic outcomes of trifluridine/tipiracil-containing regimen (TAS-102) and regorafenib-containing regimen (REG) in patients with mCRC.</p></sec><sec><title>Material and method</title><p>Patients who were diagnosed to have mCRC in 2015 to 2021 and treated with TAS-102-containing regimen or REG-containing regimen were recruited. Monotherapy or combination therapy were all allowed in this study. Oncologic outcomes were presented with progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and disease control rate (DCR).</p></sec><sec><title>Results</title><p>A total of 125 patients were enrolled into our study, accounting for 50 patients with TAS-102 and 75 patients with REG. Of these patients, 64% were treated with TAS-102 or REG monotherapy, while the remaining were treated with TAS-102 combination or REG combination. In general, the median PFS and OS were 3.7 versus 2.0 months (<italic>P</italic> = 0.006) and 9.2 versus 6.8 months (<italic>P</italic> = 0.048) in TAS-102 and REG, respectively. The ORR and DCR were 44% versus 20% (<italic>P</italic> &lt; 0.001) and 72% versus 43% (<italic>P</italic> &lt; 0.001) in TAS-102 and REG, respectively. As for treatment strategies, the survival were significantly longer in combination than in monotherapy, no matter in TAS-102 or REG group. Multivariate analysis showed TAS-102 and combination therapy were independent predictor associated with better survival.</p></sec><sec><title>Conclusions</title><p>Our results suggested that TAS-102 had better oncologic outcomes than REG in patients with mCRC, especially in combination. Further prospective trials are warranted to confirm our results.</p></sec>